Urgency Incontinence & OAB
Overactive bladder (OAB) is a symptom syndrome of urinary urgency, usually with frequency and nocturia, with or without urgency urinary incontinence (UUI), in the absence of infection or another explanatory pathology.[1] UUI is involuntary urine loss accompanied by, or immediately preceded by, a compelling urge to void.
Definitions and Epidemiology
OAB is defined clinically, not urodynamically. Detrusor overactivity (DO) may be present on filling cystometry, but there are no pathognomonic urodynamic findings that confirm OAB, and the diagnosis begins with symptoms plus exclusion of infection, hematuria, retention, and other causes.[1] DO can be absent on urodynamics in patients with UUI or mixed incontinence; a normal tracing does not rule out the clinical OAB/UUI syndrome.[1]
Population-based prevalence estimates vary with the definition used, ranging from about 7-27% in men and 9-43% in women; one review of women cites up to 12% of adults.[1][2] Prevalence and severity rise with age, and UUI is consistently more common in women than in men.[1][2] The clinical phenotype differs by sex:
| Population | Practical pattern |
|---|---|
| Men | OAB symptoms frequently coexist with benign prostatic obstruction (BPO), impaired contractility, nocturnal polyuria, or neurologic disease; storage symptoms should not be presumed to be "just prostate" or "just bladder." |
| Women | OAB/UUI commonly coexists with stress urinary incontinence, genitourinary syndrome of menopause (GSM), recurrent UTI, constipation, and pelvic organ prolapse. |
| Older adults | Frailty, cognition, mobility, diuretics, sleep apnea, edema, constipation, and caregiver access can dominate the symptom burden as much as bladder physiology. |
Pathophysiology
OAB/UUI is the storage-phase consequence of an unstable or hypersensitive bladder system. Mechanisms include:
- Myogenic DO: spontaneous detrusor contractions during filling
- Urothelial or afferent hypersensitivity: urgency at low volumes without large pressure rises
- Outlet-associated remodeling: chronic obstruction produces detrusor hypertrophy, ischemia, fibrosis, impaired compliance, and DO
- Neurogenic disinhibition: suprapontine lesions, Parkinson disease, multiple sclerosis, stroke, spinal disease, and dementia syndromes can produce urgency-predominant LUTS
- Pelvic-floor guarding or dysfunctional voiding: urgency, incomplete emptying, and pelvic pain can reinforce each other
- Urothelial mechanotransduction: PIEZO1 and PIEZO2 channels act as bladder-stretch sensors that couple filling to afferent signaling; in knockout mice, loss of PIEZO2 (and combined PIEZO1/2 loss) produces incontinence, an early mechanistic link rather than an established human diagnostic or therapeutic target[18]
- Urinary microbiome ("urobiome") dysbiosis: reduced Lactobacillus dominance and increased microbial diversity correlate with symptom severity in urgency and mixed incontinence and with treatment response to mirabegron, distinct from infection-driven urgency and still an active research area rather than a diagnostic or treatment lever[19][20]
In men older than 50 years, LUTS may be driven by BPH or bladder outlet obstruction, OAB detrusor physiology, or both.[3] This distinction is operative: outlet surgery can improve urgency when obstruction is the driver, but persistent UUI after outlet relief is common when DO or impaired compliance is the dominant substrate.
Diagnosis and Evaluation
Initial workup
The initial evaluation is usually office-based:[1][4][5]
- History: urgency triggers, frequency, nocturia, UUI episodes, pad use, fluid, caffeine and alcohol intake, constipation, UTIs, hematuria, neurologic disease, sleep apnea, edema, pelvic surgery, radiation, medications
- Symptom instruments: OAB-q, ICIQ-OAB, ICIQ-UI-SF, UDI-6; in men add IPSS to separate storage and voiding domains
- Bladder diary: 3-day diary with voided volumes, urgency grade, leakage episodes, fluid intake, nocturnal urine volume, and pad use
- Urinalysis: rule out infection, glycosuria, pyuria, and hematuria
- Post-void residual (PVR): especially before antimuscarinics, botulinum toxin, or outlet surgery; elevated PVR changes the pathway
- Focused examination: abdominal, neurologic screen, pelvic exam in women, DRE when prostate or outlet disease is relevant
- Cough stress test: when mixed incontinence is possible; urgency leakage and stress leakage frequently coexist
See Assessment Tools & Questionnaires and Urodynamics for instrument and test-selection detail.
When to escalate testing
Do not routinely perform urodynamics, cystoscopy, or imaging for uncomplicated idiopathic OAB at initial presentation.[1] Escalate when the story stops being straightforward:
| Trigger | Why it matters |
|---|---|
| Gross or microscopic hematuria | Malignancy, stone, radiation cystitis, or inflammatory pathology |
| Recurrent UTI / sterile pyuria | Infection, stone, foreign body, mesh erosion, fistula |
| Elevated PVR / weak stream / straining | BOO, detrusor underactivity, neurogenic emptying failure |
| Prior pelvic radiation or major pelvic surgery | Poor compliance, fistula, outlet stenosis, fragile tissue |
| Stage 3-4 prolapse or suspected urethral diverticulum | Anatomic driver of urgency or mixed incontinence |
| Persistent symptoms with diagnostic uncertainty before an invasive treatment | Selective urodynamics can clarify storage, emptying, or mixed dysfunction when the result would change management |
| Neurologic disease | Reclassify as possible NLUTD; upper-tract risk depends on pressure and emptying |
FUTURE trial (selective, rather than automatic, preprocedural urodynamics). This 2025 multicenter RCT randomized 1,103 women with refractory OAB or urgency-predominant mixed incontinence to comprehensive clinical assessment with or without urodynamics; 1,099 were included in the analysis after four postrandomization exclusions. At 15- or 24-month final follow-up, 117/496 women (23.6%) assigned urodynamics plus clinical assessment and 114/503 (22.7%) assigned clinical assessment alone rated their bladder symptoms 'much improved' or 'very much improved' (adjusted OR 1.12, 95% CI 0.73–1.74). This supports selecting the test for a clinical question; it does not remove its role in suspected obstruction, impaired compliance, unexplained retention, or NLUTD.[9]
Sex-Specific Patterns
Men
Male OAB/UUI is often a mixed bladder-prostate problem. Storage symptoms (urgency, frequency, nocturia, UUI) and voiding symptoms (weak stream, hesitancy, intermittency, straining) should be scored separately, because treatment failure is common when one domain is treated while the other is ignored.[3][6]
| Finding | Implication |
|---|---|
| High IPSS storage score, low PVR, good stream | Treat as OAB-predominant LUTS |
| High voiding score, enlarged prostate, elevated PVR | Assess for outlet obstruction and detrusor underactivity before selecting treatment; high PVR and prostate size alone do not establish obstruction.[24] |
| Urgency after TURP / HoLEP / prostatectomy | Consider persistent DO, infection, bladder-neck contracture, urethral stricture, or radiation cystitis |
| Parkinson disease, stroke, MS, dementia | Avoid assuming BPH; consider neurogenic OAB and cognition-safe therapy |
Antimuscarinics and β3 agonists can be used in men with OAB symptoms, including in selected men with treated or monitored BPH, but PVR and obstructive symptoms affect safety; the EAU 2026 male LUTS guideline weakly recommends against antimuscarinics when PVR is >150 mL and advises regular symptom and PVR reassessment during antimuscarinic treatment.[1][3][6][24]
Women
Female OAB/UUI is commonly entangled with stress incontinence, prolapse, menopause-related tissue changes, constipation, recurrent UTI, and pelvic-floor overactivity.[4][5]
| Finding | Implication |
|---|---|
| Positive cough stress test | Treat as mixed incontinence; anti-incontinence surgery may worsen urgency in susceptible patients |
| GSM / atrophic mucosa | For GSM with comorbid OAB, local low-dose vaginal estrogen may be offered to improve genitourinary symptoms ; for GSM with recurrent UTI, it is recommended to reduce future UTI risk ;[14] systemic estrogen is not used to treat incontinence.[5] |
| Advanced prolapse | Reduction testing and PVR clarify obstruction versus increased bladder sensation |
| Prior sling or mesh surgery | Consider obstruction, erosion, recurrent SUI, or pain-driven urgency |
"Sensory urgency" was retired from ICS terminology; distinguish increased bladder sensation or an early, still-deferrable desire to void from urgency itself, a sudden compelling desire that is difficult to defer. This is a symptom distinction for history-taking, not a separate urodynamic diagnosis, and it does not by itself exclude detrusor overactivity.[22]
Management
Behavioral and pelvic-floor therapy
Offer bladder training to all patients and behavioral therapies to all patients ; these can continue alongside medication or a procedure.[1][7]
- Bladder training: progressive voiding intervals with urge suppression
- Timed voiding: particularly useful for frailty, cognition, or caregiver-dependent toileting
- Fluid timing: avoid excess evening intake; treat nocturnal polyuria rather than blaming all nocturia on OAB
- Caffeine and alcohol reduction: trial elimination when diary shows a temporal relationship; in a case-control study of 259 women with incontinence symptoms undergoing urodynamics, intake above 400 mg/day was associated with higher odds of detrusor instability than intake below 100 mg/day after adjustment for age and smoking (OR 2.4, 95% CI 1.1–6.5); causality was not established[21]
- Constipation treatment: rectal loading worsens urgency and emptying
- Pelvic floor physical therapy: urge-suppression contractions, relaxation of overactive pelvic floor, and coordination training
- Weight loss and exercise: especially when mixed incontinence coexists
See Behavioral Therapy for OAB & UUI for bladder-training protocols, urge-suppression teaching, CBT-informed approaches, weight-loss evidence, and combination behavioral and drug therapy data. In men, a randomized trial found that a stepped strategy beginning with behavioral therapy, then adding drug therapy when needed, is reasonable for OAB symptoms.[7]
Pharmacotherapy
Medication selection should account for cognition, constipation, glaucoma risk, blood pressure, renal function, PVR, polypharmacy, and the need for concurrent outlet therapy.
| Class | Role | Reconstructive / functional cautions |
|---|---|---|
| Antimuscarinics | Reduce urgency, frequency, and UUI episodes | Dry mouth, constipation, blurred vision, retention risk; avoid or minimize in cognitively vulnerable older adults |
| β3 agonists (mirabegron, vibegron) | Similar efficacy with less dry mouth and less cognitive burden | Mirabegron can raise blood pressure; check baseline BP and interactions, monitor BP periodically, and note that it is not recommended when SBP ≥180 mm Hg or DBP ≥110 mm Hg.[26] |
| Combination OAB therapy | β3 agonist + antimuscarinic when monotherapy is inadequate | Higher efficacy but more adverse effects and cost; monitor PVR in at-risk patients |
| α-blocker / 5α-reductase inhibitor / tadalafil in men | Treats coexisting BPH/outlet symptoms, not OAB itself | Persistent storage symptoms after outlet therapy may still require OAB-directed treatment |
| Vaginal estrogen in women | For GSM with OAB, local low-dose vaginal estrogen may be offered ; for GSM with recurrent UTI, it is recommended to reduce future UTI risk .[14] | Not a primary OAB drug; systemic estrogen is not used for incontinence treatment.[5] |
The AUA/SUFU guideline recommends offering antimuscarinic medications or β3 agonists to patients with OAB , with shared decision-making around side effects and patient priorities.[1] The guideline advises discussing the possible association between antimuscarinics and dementia or cognitive impairment, and a β3 agonist is a reasonable first choice in older or cognitively vulnerable patients when blood pressure and coverage allow.[1] Use antimuscarinics with extreme caution in narrow-angle glaucoma, impaired gastric emptying, or prior retention.[1] A 2021 review described mirabegron as the most studied pharmacologic option for male OAB at that time.[6] COURAGE randomized 1,105 men with persistent OAB symptoms while taking BPH medication to vibegron 75 mg or placebo; among 1,080 men in the efficacy analysis set, the week 12 between-group difference was 0.95 fewer urgency episodes per day (95% CI 0.54–1.37 fewer).[25] The EAU 2026 male LUTS guideline gives a weak recommendation to add a β3 agonist for persistent storage symptoms on α-blocker monotherapy.[24]
Minimally invasive therapy
See the OAB & UUI treatment database for procedural selection and comparisons.
The 2024 AUA/SUFU guideline permits minimally invasive therapy through shared decision-making without requiring prior behavioral or medication trials . It also recommends offering SNM, percutaneous tibial nerve stimulation, and/or intradetrusor botulinum toxin after inadequate response or intolerable adverse effects from behavioral or drug treatment . Discuss procedure burden, durability, adverse effects, and patient priorities; clinical guideline sequencing does not itself change product labeling or coverage criteria.[1]
| Therapy | Best candidate | Key counseling point |
|---|---|---|
| Intradetrusor onabotulinumtoxinA | Refractory OAB-wet, medication intolerance, patient comfortable with cystoscopic repeat treatment | UTI and retention risk; patient must be willing and able to perform CIC if needed |
| Sacral neuromodulation | Refractory urgency-frequency, UUI, non-obstructive retention, mixed storage/emptying phenotypes | Requires test phase, implanted device, MRI-conditional device planning, battery/revision counseling |
| PTNS | Patient preferring low-risk office neuromodulation | Typically 12 weekly office sessions followed by maintenance as needed; low systemic adverse-effect burden |
| Implantable tibial nerve stimulation | Patient with UUI preferring an implanted tibial stimulator to repeated office PTNS visits | Requires implantation and device-specific counseling; see the procedure page.[1] |
| TTNS | Patient preferring noninvasive surface-electrode stimulation at home | Optimal schedule is not established; evidence and treatment burden differ from PTNS.[1][13] |
Comparative evidence and harms should inform selection, rather than treating the procedures as interchangeable.[8]
The EAU 2026 female LUTS guideline is more stepwise. It recommends bladder training as first-line therapy and offers anticholinergics or β3 agonists to women who fail conservative management , considering extended-release anticholinergic formulations whenever possible and offering early review after either drug (both Strong). OnabotulinumtoxinA 100 U is offered for OAB/UUI refractory to conservative or drug treatment , after warning about limited duration, UTI and possible prolonged intermittent catheterization. SNM is offered for UUI refractory to anticholinergic therapy , and PTNS as an option . EAU advises caution with long-term anticholinergic use in older women, especially with cognitive risk, and assessment of anticholinergic burden (both Strong). It also recommends vaginal estrogen for women with LUTS and genitourinary syndrome of menopause , monitoring PVR during treatments that can worsen emptying , and against routine urodynamics before first-line treatment of uncomplicated OAB , reserving testing for cases in which the result may change invasive treatment or the diagnosis is uncertain .[13]
In men considering bladder botulinum toxin, assess baseline emptying and possible outlet obstruction rather than assuming a fixed sex-specific catheterization risk. A 146-man retrospective series associated a higher bladder outlet obstruction index with more complications[11]; a post-hoc subgroup analysis of a Japanese phase 3 trial (100 U) found week-2 PVR of 200 mL or more in 3 of 11 men with PSA 1.5 ng/mL or higher, none of the men with lower PSA, and no symptom benefit in the higher-PSA group.[12]
Energy-based treatment update (July 2026). A double-blind RCT of 140 women compared three monthly microablative vaginal radiofrequency sessions with sham, with behavioral therapy in both groups. Radiofrequency did not outperform sham for OAB symptoms at six months; adverse events occurred in 44.2% versus 22.9%.[10] The 2024 AUA/SUFU guideline likewise judges the laser and radiofrequency evidence in OAB to be poor quality and does not recommend either.[1]
Reconstructive end of the pathway
Augmentation cystoplasty or urinary diversion is rarely needed for idiopathic OAB in the modern botulinum and neuromodulation era, but remains relevant for severe refractory storage failure, poor compliance, high-pressure NLUTD, radiation-damaged bladder, or hostile outlet situations. In those patients, OAB/UUI should be reframed as a safe-storage problem, not merely a symptom-control problem. For augmentation of refractory OAB/UUI, the EAU 2026 female LUTS guideline recommends confirming willingness and ability to perform intermittent catheterization and counseling about lifelong surveillance , including cystoscopic surveillance in women at least 10 years after augmentation ; for diversion, it recommends confirming stoma acceptance and discussing the small malignancy risk .[13]
A retrospective series of 51 women with non-neurogenic UUI (27 with interstitial cystitis) reported complete continence in 27/51 (53%), occasional leaks in 13/51 (25%), disabling UUI in 9/51 (18%), regular self-catheterization in 20/51 (39%), and satisfaction in 27/51 (53%) at a mean 75.4 months.[15] Revision of the augmentation was reported in a wide range (roughly 5–40%) across series, and metabolic acidosis required bicarbonate in a minority.[16] The EAU 2026 female LUTS guideline weakly recommends urinary diversion for OAB/UUI only after less invasive treatment has failed, with stoma acceptance and counseling about the small possible malignancy risk; it describes the evidence for urinary diversion specifically in idiopathic OAB or UUI as limited.[13] A separate 33-patient neurogenic-bladder ileal-conduit series reported perioperative complications in 12/33 and pyocystitis in 4/19 patients who retained the bladder at a mean 48-month follow-up.[17]
Follow-Up and Treatment Failure
Track the same measures used at baseline: diary episodes, urgency grade, nocturia, pad count, PVR, adverse effects, bowel function, and patient-defined bother. If a patient "fails OAB treatment," reassess the diagnosis before escalating:
- Is the leakage actually stress-predominant or fistulous?
- Is nocturia driven by nocturnal polyuria, edema, sleep apnea, or diuretics?
- Is there occult retention from BOO, sling obstruction, antimuscarinic effect, or detrusor underactivity?
- Is recurrent UTI, stone, mesh erosion, radiation cystitis, or bladder pain syndrome driving urgency?
- Is neurologic disease evolving into NLUTD? New urgency, frequency, or incontinence accompanied by gait disturbance or cognitive change can signal occult neurologic disease, including normal-pressure hydrocephalus; arrange neurologic referral.[23][27]
See Also
- OAB & UUI treatment database
- Behavioral Therapy for OAB & UUI
- Pelvic Floor Physical Therapy
- Intradetrusor onabotulinumtoxinA
- Sacral Neuromodulation
- Percutaneous Tibial Nerve Stimulation
- Urodynamics
- Mixed Urinary Incontinence
- Neurogenic Lower Urinary Tract Dysfunction
Podcasts
Videos
References
1. Cameron AP, Chung DE, Dielubanza EJ, et al. "The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder." J Urol. 2024;212(1):11-20. doi:10.1097/JU.0000000000003985
2. Raju R, Linder BJ. "Evaluation and Treatment of Overactive Bladder in Women." Mayo Clin Proc. 2020;95(2):370-377. doi:10.1016/j.mayocp.2019.11.024
3. Wei JT, Dauw CA, Brodsky CN. "Lower Urinary Tract Symptoms in Men: A Review." JAMA. 2025;334(9):809-821. doi:10.1001/jama.2025.7045
4. Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. "Urinary Incontinence in Women: A Review." JAMA. 2017;318(16):1592-1604. doi:10.1001/jama.2017.12137
5. Hu JS, Pierre EF. "Urinary Incontinence in Women: Evaluation and Management." Am Fam Physician. 2019;100(6):339-348. PMID:31524367
6. De Nunzio C, Brucker B, Bschleipfer T, et al. "Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men." Eur Urol. 2021;79(4):492-504. doi:10.1016/j.eururo.2020.12.032
7. Burgio KL, Kraus SR, Johnson TM, et al. "Effectiveness of Combined Behavioral and Drug Therapy for Overactive Bladder Symptoms in Men: A Randomized Clinical Trial." JAMA Intern Med. 2020;180(3):411-419. doi:10.1001/jamainternmed.2019.6398
8. Farag F, Sakalis VI, Monagas Arteaga S, et al. "What Are the Short-term Benefits and Potential Harms of Therapeutic Modalities for the Management of Overactive Bladder Syndrome in Women? A Review of Evidence Under the Auspices of the European Association of Urology, Female Non-neurogenic Lower Urinary Tract Symptoms Guidelines Panel." Eur Urol. 2023;84(3):302-312. doi:10.1016/j.eururo.2023.05.014
9. Abdel-Fattah M, Chapple C, Cooper D, et al. "Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms (FUTURE) in the UK: a multicentre, superiority, parallel, open-label, randomised controlled trial." Lancet. 2025;405(10484):1057–1068. doi:10.1016/S0140-6736(24)01886-5. Detailed primary report: Abdel-Fattah M, Chapple C, Breeman S, et al. Health Technol Assess. 2025;29(27). Participant flow and analysis population; clinical results.
10. Alvear C, Juliato CRT, Lunardi ALB, et al. "Microablative Radiofrequency Versus Sham for Overactive Bladder: A Randomized Controlled Trial With 6 Months Follow up." Neurourol Urodyn. Published online July 6, 2026. doi:10.1002/nau.70362
11. Mateu Arrom L, Mayordomo Ferrer O, Sabiote Rubio L, et al. "Treatment Response and Complications after Intradetrusor OnabotulinumtoxinA Injection in Male Patients with Idiopathic Overactive Bladder Syndrome." J Urol. 2020;203(2):392–397. doi:10.1097/JU.0000000000000525
12. Yokoyama O, Honda M, Yamanishi T, et al. "Efficacy and safety of onabotulinumtoxinA in patients with overactive bladder: subgroup analyses by sex and by serum prostate-specific antigen levels in men from a randomized controlled trial." Int Urol Nephrol. 2021;53(11):2243–2250. doi:10.1007/s11255-021-02962-z.
13. European Association of Urology. EAU Guidelines on Management of Non-Neurogenic Female Lower Urinary Tract Symptoms (LUTS) (Limited Update March 2026). Guideline.
14. Kaufman MR, Ackerman AL, Amin KA, et al. "The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause." J Urol. 2025;214(3):242-250. doi:10.1097/JU.0000000000004589
15. Awad SA, Al-Zahrani HM, Gajewski JB, Bourque-Kehoe AA. "Long-term results and complications of augmentation ileocystoplasty for idiopathic urge incontinence in women." Br J Urol. 1998;81(4):569-573. doi:10.1046/j.1464-410x.1998.00549.x
16. Biers SM, Venn SN, Greenwell TJ. "The past, present and future of augmentation cystoplasty." BJU Int. 2012;109(9):1280-1293. doi:10.1111/j.1464-410X.2011.10650.x
17. Chartier-Kastler EJ, Mozer P, Denys P, et al. "Neurogenic bladder management and cutaneous non-continent ileal conduit." Spinal Cord. 2002;40(9):443-448. doi:10.1038/sj.sc.3101346
18. Dalghi MG, Ruiz WG, Clayton DR, et al. "Functional roles for PIEZO1 and PIEZO2 in urothelial mechanotransduction and lower urinary tract interoception." JCI Insight. 2021;6(19):e152984. doi:10.1172/jci.insight.152984
19. Zhou Z, Qiu Y, Li K, et al. "Unraveling the impact of Lactobacillus spp. and other urinary microorganisms on the efficacy of mirabegron in female patients with overactive bladder." Front Cell Infect Microbiol. 2022;12:1030315. doi:10.3389/fcimb.2022.1030315
20. Shaker P, Roshani Z, Timajchi E, et al. "The Role of Urinary Microbiome Analysis in the Diagnostic Approach and Management of Urinary Incontinence: A Systematic Review." Life (Basel). 2025;15(2):309. doi:10.3390/life15020309
21. Arya LA, Myers DL, Jackson ND. "Dietary caffeine intake and the risk for detrusor instability: a case-control study." Obstet Gynecol. 2000;96(1):85-89. doi:10.1016/s0029-7844(00)00808-5
22. Abrams P, Cardozo L, Fall M, et al. "The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society." Neurourol Urodyn. 2002;21(2):167-178. doi:10.1002/nau.10052
23. Wei DY, Drake MJ. "Undiagnosed neurological disease as a potential cause of male lower urinary tract symptoms." Curr Opin Urol. 2016;26(1):11-16. doi:10.1097/MOU.0000000000000243
24. European Association of Urology. EAU Guidelines on the Management of Non-neurogenic Male LUTS (2026). Guideline.
25. Staskin D, Owens-Grillo J, Thomas E, et al. "Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial." J Urol. 2024;212(2):256–266. doi:10.1097/JU.0000000000003999
26. Astellas Pharma US. MYRBETRIQ (mirabegron) prescribing information. Revised April 2021. DailyMed, section 5.1. Label.
27. Roy HA, Nettleton J, Blain C, et al. "Assessment of patients with lower urinary tract symptoms where an undiagnosed neurological disease is suspected: A report from an International Continence Society consensus working group." Neurourol Urodyn. 2020;39(8):2535-2543. doi:10.1002/nau.24469